Hepatocyte-specific miR-33 deletion attenuates NAFLD-NASH-HCC progression

Area of Science:

• Hepatology and Molecular Biology
• Metabolic Diseases
• Cancer Biology

Background:

• Non-alcoholic fatty liver disease (NAFLD) progression involves complex mechanisms, hindering therapeutic development.
• MicroRNAs (miRNAs) are key regulators of biological processes and potential therapeutic targets for complex diseases.
• Hepatic miR-33 is an important regulator of lipid metabolism implicated in NAFLD.

Approach:

• Investigated the role of hepatic miR-33 in NAFLD progression using a mouse model.
• Studied the effects of specific suppression of miR-33 in hepatocytes (miR-33 HKO).
• Analyzed molecular mechanisms including lipid biosynthesis, mitochondrial function, AMPK activation, and YAP/TAZ pathway.

Key Points:

• miR-33 is overexpressed in NAFLD hepatocytes.
• miR-33 suppression in hepatocytes improved insulin resistance, steatosis, and inflammation.
• miR-33 deficiency reduced lipid biosynthesis, enhanced mitochondrial fatty acid oxidation, and improved mitochondrial function.
• AMPKα activation was increased in miR-33 deficient hepatocytes, attenuating liver disease.
• Reduced lipid accumulation and injury decreased YAP/TAZ activity, potentially limiting hepatocellular carcinoma (HCC) progression.

Conclusions:

• Specific suppression of hepatic miR-33 ameliorates multiple aspects of NAFLD/NASH.
• Targeting miR-33 may offer a therapeutic strategy for NAFLD, NASH, and HCC at various disease stages.